Paul Tudor Jones Rigel Pharmaceuticals Inc Transaction History

Tudor Investment Corp Et Al

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.5 - $4.5 $503,881 - $647,847	-143,966 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.09 - $4.54 $444,854 - $653,605	143,966 New	143,966 $625,000
Q1 2020 May 15, 2020	SELL	$1.27 - $3.0 $176,542 - $417,030	-139,010 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$1.6 - $2.43 $168,129 - $255,346	-105,081 Reduced 43.05%	139,010 $297,000
Q3 2019 Nov 14, 2019	BUY	$1.63 - $2.62 $110,730 - $177,984	67,933 Added 38.56%	244,091 $456,000
Q2 2019 Aug 14, 2019	BUY	$2.02 - $2.61 $183,367 - $236,925	90,776 Added 106.32%	176,158 $460,000
Q1 2019 May 15, 2019	BUY	$2.0 - $2.65 $170,764 - $226,262	85,382 New	85,382 $219,000
Q1 2018 May 15, 2018	SELL	$3.54 - $4.54 $197,553 - $253,359	-55,806 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $180,253 - $239,965	55,806	55,806 $217,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.